Christopher Degnan
Chief Financial OfficerMr. Christopher Degnan, also known as Chris, CPA is Chief Financial Officer of UroGen Pharma Ltd. from October 2024. Mr. Degnan served as Chief Financial Officer of Galera Therapeutics, Inc. since October 21, 2019 until 2024 and also served as its Secretary since October 2019 until October 2021. He serves as Chief Financial Officer at Urogen Pharma, Inc Mr. Degnan served as the Chief Financial Officer of Verrica Pharmaceuticals Inc. since March 2018 until October 2019. Mr. Degnan held roles of increasing responsibility at Endo International plc, beginning in November 2014, where he served as the Vice President of Finance, Corporate FP&A and International Pharmaceuticals Segment Chief Financial Officer from December 2016 to March 2018. He was the Vice President of Finance, Chief Financial Officer for Endo’s U.S. Branded Pharmaceuticals segment from March 2016 to December 2016. Prior to joining Endo, Mr. Degnan held roles of increasing responsibility at AstraZeneca plc, a global biopharmaceutical company, beginning in 2004, most recently as Senior Finance Director, U.S. Commercial Finance from July 2013 to November 2014 and as the Senior Finance Director, U.S. Branded Pharmaceuticals from November 2014 to March 2016. He is a Certified Public Accountant in the State of Pennsylvania (voluntary inactive status) and holds a B.B.A. degree in Accountancy from the University of Notre Dame.
Positions
- Company NameUroGen Pharma Ltd.Stock CodeURGNPositionChief Financial OfficerColleagues
- EAElizabeth A. BarrettPresident, CEO & Director
- ASArie S. BelldegrunIndependent Chairman
- JDJason Drew SmithGeneral Counsel, Chief Compliance Officer & Corporate Secretary
- MPMark P. SchoenbergChief Medical Officer
- VIVincent I. PerroneSenior Director of Investor Relations
- HLHerbert LeporChairman of Scientific Advisory Board
- CMCynthia Marie ButittaIndependent Director
- LSLeana S. WenIndependent Director
